EGRIFTA WRTM Has a Unique Mechanism of Action Designed to Address the Reduction in Growth Hormone (GH) Concentrations Associated with EVAF1-3

A reduction in GH concentrations has been observed in PWH4

  • GH is essential in the formation and function of fat cells and plays a key role in the overall regulation of fat metabolism.4
  • VAT accumulation is predictive of low GH levels; in PWH, there is a significant inverse relationship between increasing VAT surface area and lower GH levels.1
  • EVAF may directly reduce GH levels, while diminished GH and elevated IGF-1 levels further drive EVAF buildup, creating a maladaptive feedback loop.2
  • EGRIFTA WRTM is an analog of GHRH that stimulates the body to secrete its own GH in a pulsatile manner, resulting in both anabolic and lipolytic effects.3
  • By supporting endogenous GH release without altering pulse frequency, EGRIFTA WRTM mimics the body’s natural hormone rhythm.5

The solution to EVAF may not be diet and exercise alone.6

Watch the video to learn how EGRIFTA WRTM works

Ready to learn more about EGRIFTA WRTM?

Dive into the 26‑week and 52‑week efficacy outcomes for change in EVAF, waist circumference, lean body mass, trunk fat, and more.

EVAF = excess visceral abdominal fat; GH = growth hormone; GHRH = growth hormone releasing hormone; IGF-1 = insulin‑like growth factor 1; PWH = people with HIV; VAT = visceral adipose tissue.

References:

  1. Rietschel P, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metabolism. 2001;86(2):504-510.
  2. Srinisava S. Understanding Growth Hormone Deficiency in HIV Lipodystrophy. NEPTCC Newsletter. 2017;23(1):1-2.
  3. Theratechnologies Inc. EGRIFTA WRTM (tesamorelin) for injection Prescribing Information. March, 2025.
  4. Stanley TL, et al. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59-65.
  5. Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158.
  6. Lake JE, et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clin Infect Dis. 2017;64(10):1422-1429.

Let’s keep in touch

Enter your contact details to stay up to date with the latest developments from Theratechnologies.

By clicking the “Sign up” button below, I consent to receiving communications from Theratechnologies.

* Mandatory field.

Thank You for Signing Up!

We look forward to keeping you informed with the latest news and updates from Theratechnologies.

IMPORTANT SAFETY INFORMATION ABOUT EGRIFTA WRTM (TESAMORELIN) FOR INJECTION

Indication

EGRIFTA WRTM is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Limitations of Use:

  • The impact and safety of EGRIFTA WRTM on cardiovascular health has not been studied.
  • EGRIFTA WRTM is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA WRTM helps improve compliance with anti-retroviral medications.

Contraindications:

Do not use EGRIFTA WRTM if patient:

  • Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
  • Has active cancer.
  • Is allergic to tesamorelin or any of the ingredients in EGRIFTA WRTM.
  • Is pregnant or planning to become pregnant.

Warnings and Precautions

  • Increased risk of neoplasms: Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA WRTM. EGRIFTA WRTM should be discontinued if the patient has evidence of recurrent malignancy.
  • Elevated IGF-1: Regularly monitor IGF-1 levels in all patients during EGRIFTA WRTM therapy. Consider discontinuing in patients with persistent elevations (e.g., >3 SDS).
  • Fluid retention: May include edema, arthralgia, and carpal tunnel syndrome.
  • Glucose intolerance or diabetes mellitus: May develop with EGRIFTA WRTM treatment. Evaluate glucose status prior to and during therapy with EGRIFTA WRTM.
  • Hypersensitivity reactions: Advise patients to seek immediate medical attention if suspected.
  • Injection site reactions: Advise patients to rotate sites to different areas of the abdomen to decrease injection site reactions.
  • Increased mortality in patients with acute critical illness: Consider discontinuation in critically ill patients.

Drug Interactions

  • EGRIFTA WRTM had no significant impact on the pharmacokinetic profiles of simvastatin in healthy subjects.
  • Monitor patients for potential interactions when administering EGRIFTA WRTM in combination with other drugs known to be metabolized by CYP450 liver enzyme.
  • Patients on glucocorticoids may require dosage adjustment upon initiation of EGRIFTA WRTM.

Use in Specific Populations

  • Lactation: Mothers should not breastfeed if they receive EGRIFTA WRTM.
  • Pediatric use: Safety and effectiveness in pediatric patients have not been established.
  • Geriatric use: There is no information on the use of EGRIFTA WRTM in patients greater than 65 years of age.

Adverse Reactions

The most commonly reported adverse reactions include injection site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

For complete disclosure of EGRIFTA WRTM product information, please read the Full Prescribing Information, Patient Information, and Patient Instructions for Use.

For more information about EGRIFTA WRTM, contact THERA patient support® program toll-free at 1-833-23THERA (1-833-238-4372). To report suspected adverse reactions, contact THERA patient support® program or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.